Deng X. et al. (2022) proposed that the cardiovascular benefits of empagliflozin, another SGLT2 inhibitor, were associated with gut microbiota. However, another research showed that dapagliflozin could not altered the fecal microbiome in patients with T2DM (van Bommel et al., 2020). The inconsistency may be attributable to the unparallel analysis of gut microbiota and selection of the ethnicity, environment, diet and socio-economic variables (Ahmad et al., 2019). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.